Jonathan Clabeaux, MD
Orthopaedic Surgery · Seattle, WANPI 1235302696
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $48,051 of the $55,648 with a category attached, or 86.3%. Medacta USA, Inc. accounts for 99.8% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $32,475 and has fallen 99.9% since, to $21 in 2025. Among orthopaedic surgery clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 46 payments — averaging $1209.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medacta USA, Inc.$56K
- Zimmer Biomet$89
- Johnson & Johnson$21
What the payments were for
- Consulting fees$48,05186%
- Travel & lodging$6,62312%
- Food & beverage$9742%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medacta USA, Inc. | 44 | $55,538 |
| Zimmer Biomet | 1 | $89 |
| Johnson & Johnson | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GMK SPHERE$30,149
- AMISTEM$10,764
- GMK Sphere Revision System$7,650
How this compares
$55,648 in reported general payments places this provider in the 90th percentile of 495 orthopaedic surgery providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Meloxicam | 147 | $1,722 |
| Celecoxib | 15 | $589 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Seattle
- James PritchettSeattle$6.4M
- James CrutcherSeattle$3.5M
- Keith MayoSeattle$3.1M
- Matthew SaltzmanSeattle$1.8M
- Burt YaszaySeattle$1.3M
- Sean ToomeySeattle$1.2M
- Robert HartSeattle$942K
- Jeffrey RohSeattle$604K
- Michael BrageSeattle$496K
- Daniel SchwartzSeattle$424K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.